Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A First-in-Human, Open-Label, Multi-Center Phase 1 Study of TST003 in Subjects With Locally Advanced or Metastatic Solid Tumors

NCT05731271 is registered in ClinicalTrials.gov with Transcenta Therapeutics (Hangzhou) Co., Ltd. as lead sponsor.

NCT NCT05731271
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05731271 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A First-in-Human, Open-Label, Multi-Center Phase 1 Study of TST003 in Subjects With Locally Advanced or Metastatic Solid Tumors
Lead sponsor
Transcenta Therapeutics (Hangzhou) Co., Ltd.
Phase
Phase 1/2
Overall status
Active, not recruiting
Start date
February 8, 2023
Completion date
September 30, 2027
Enrollment
111 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

colorectal adenocarcinoma, locally advanced solid tumor, metastatic tumor